Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Cybin Inc (CYBN)

Cybin Inc (CYBN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 59,879
  • Shares Outstanding, K 177,524
  • Annual Sales, $ 0 K
  • Annual Income, $ -53,960 K
  • 60-Month Beta 1.14
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.25
Trade CYBN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.27
  • Most Recent Earnings -0.05 on 11/14/22
  • Next Earnings Date 11/21/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.07
  • Number of Estimates 4
  • High Estimate -0.05
  • Low Estimate -0.08
  • Prior Year -0.08
  • Growth Rate Est. (year over year) +12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3200 +0.75%
on 12/07/22
0.4800 -32.83%
on 11/10/22
-0.1326 (-29.14%)
since 11/07/22
3-Month
0.3200 +0.75%
on 12/07/22
0.9999 -67.76%
on 09/08/22
-0.6139 (-65.57%)
since 09/07/22
52-Week
0.3200 +0.75%
on 12/07/22
1.3300 -75.76%
on 12/08/21
-0.9776 (-75.20%)
since 12/07/21

Most Recent Stories

More News
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment

Atai, Biogen, and Sage are working to develop new treatments for mental illness.

BIIB : 292.15 (+0.23%)
ESALY : 71.3000 (+1.29%)
ATAI : 3.18 (+0.63%)
SAGE : 40.64 (-2.33%)
ARKK : 34.35 (-0.78%)
SEEL : 1.0700 (-6.96%)
CMPS : 10.91 (+5.61%)
MNMD : 2.82 (+1.44%)
CYBN : 0.3224 (-4.42%)
Cybin Presents CYB003 Preclinical Data at 2022 American College of Neuropsychopharmacology Annual Meeting

Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , today announced that the Company presented...

CYBN.NE : 0.430 (-2.27%)
CYBN : 0.3224 (-4.42%)
Cybin (NYSE American: CYBN) (NEO: CYBN) Announces Q2 Results, Business Highlights

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), has reported unaudited financial results for its second quarter ended Sept....

CYBN.NE : 0.430 (-2.27%)
CYBN : 0.3224 (-4.42%)
Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022

Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , today announced that the Company presented...

CYBN.NE : 0.430 (-2.27%)
CYBN : 0.3224 (-4.42%)
Cybin Inc. Reports Second Quarter Financial Results and Recent Business Highlights

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , today reported unaudited financial...

CYBN.NE : 0.430 (-2.27%)
CYBN : 0.3224 (-4.42%)
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates

EQNX::TICKER_START (NASDAQ:SAGE),NASDAQ:NERV),(NASDAQ:ATAI),(NYSE:CYBN),(TSXV:MRVL),(NEO:CYBN), EQNX::TICKER_END

CYBN.NE : 0.430 (-2.27%)
MRVL.VN : 0.150 (+7.14%)
SAGE : 40.64 (-2.33%)
NERV : 3.04 (+1.67%)
ATAI : 3.18 (+0.63%)
CYBN : 0.3224 (-4.42%)
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - Anti-anxiety drugs are medications that are used to treat anxiety disorders that are mainly used to...

MRVL.VN : 0.150 (+7.14%)
SAGE : 40.64 (-2.33%)
NERV : 3.04 (+1.67%)
ATAI : 3.18 (+0.63%)
CYBN : 0.3224 (-4.42%)
Cybin Provides Progress Update on its CYB004-E Phase 1 Trial

Cybin Inc. ( NEO:CYBN ) (NYSE AMERICAN:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , is pleased to announce that its...

CYBN.NE : 0.430 (-2.27%)
CYBN : 0.3224 (-4.42%)
Cybin (NYSE American: CYBN) (NEO: CYBN) Announces Schedule for Upcoming Events

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced its participation in upcoming investor events. The company’s...

CYBN.NE : 0.430 (-2.27%)
CYBN : 0.3224 (-4.42%)
Cybin to Participate in the Jefferies London Healthcare Conference and Upcoming Investor Events

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , is pleased to announce its participation...

CYBN.NE : 0.430 (-2.27%)
CYBN : 0.3224 (-4.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Cybin Inc. is a biotechnology company. It is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin Inc. is based in Toronto, Canada.

See More

Key Turning Points

3rd Resistance Point 0.3881
2nd Resistance Point 0.3740
1st Resistance Point 0.3482
Last Price 0.3224
1st Support Level 0.3083
2nd Support Level 0.2942
3rd Support Level 0.2684

See More

52-Week High 1.3300
Fibonacci 61.8% 0.9442
Fibonacci 50% 0.8250
Fibonacci 38.2% 0.7058
Last Price 0.3224
52-Week Low 0.3200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar